Secretory-Defect Distal Renal Tubular Acidosis Is Associated with Transporter Defect in H+-ATPase and Anion Exchanger-1
Jin Suk Han*,
Gheun-Ho Kim,
Jin Kim,
Un Sil Jeon,
Kwon Wook Joo¶,
Ki Young Na*,
Curie Ahn*,
Suhnggwon Kim*,
Sang Eun Lee|| and
Jung Sang Lee*
*Department of Internal Medicine, Seoul National University, Clinical Research Institute of Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea; Department of Anatomy, Catholic University, Seoul, Korea; Department of Internal Medicine, Gyeong-sang National University, Chinju, Korea; ¶Department of Internal Medicine, Gachon Medical School, Incheon, Korea; ||Department of Urology, Seoul National University, Seoul, Korea.
Correspondence to: Dr. Jung Sang Lee, Department of Internal Medicine, Seoul National University, Research Institute of Seoul National University Hospital, 28, Yongun-dong, Chongno-gu, Seoul, 110-744, South Korea. Phone: +82-2-760-2265; Fax : +82-2-742-9031; E-mail : jsleemd{at}plaza.snu.ac.kr
ABSTRACT. Recent progress in molecular physiology has permittedus to understand pathophysiology of various channelopathiesat a molecular level. The secretion of H+ from -intercalatedcells is mediated by apical plasma membrane H+-ATPase and basolateralplasma membrane anion exchanger-1 (AE1). Studies have demonstratedthe lack of H+-ATPase immunostaining in the intercalated cellsin a few patients with distal renal tubular acidosis (dRTA).Mutations in H+-ATPase and AE1 gene have recently been reportedto cause dRTA. This study extends the investigation of the roleof transporter defect in dRTA by using immunohistochemical methods.Eleven patients with hyperchloremic metabolic acidosis werediagnosed functionally to have secretory-defect dRTA: urinepH >5.5 during acidemia, normokalemia or hypokalemia, andurine-to-blood pCO2 <25 mmHg during bicarbonaturia. Renalbiopsy tissue was obtained from each patient, and immunohistochemistrywas carried out using antibodies to H+-ATPase and AE1. For comparison,renal tissues from the patients who had no evidences of distalacidification defect by functional studies were used: four withglomerulopathy or tubulointerstitial nephritis (disease controls)and three from nephrectomized kidneys for renal cell carcinoma(normal controls). The H+-ATPase immunoreactivity in -intercalatedcells was almost absent in all of the 11 patients with secretory-defectdRTA. In addition, 7 of 11 patients with secretory-defect dRTAwere accompanied by negative AE1 immunoreactivity. In both diseasecontrols and normal controls, the immunoreactivity of H+-ATPaseand AE1 was strong in -intercalated cells. In conclusion, significantdefect in acid-base transporters is the major cause of secretory-defectdRTA.
Renal tubular acidosis comprises a diverse group of tubulardisorders that are characterized by an impairment of urinaryacidification. Urinary acidification can be divided into proximaland distal categories on the basis of which nephron segmentis involved in H+ secretion and HCO3- reabsorption. The proximaltubule is the major site for reabsorption of filtered HCO3-,and the distal nephron, primarily the collecting duct, is responsiblefor reabsorption of the remaining 10 to 20% of filtered HCO3-and for elimination of excess H+ (1).
The importance of the apical H+-ATPase and basolateral anionexchanger-1 (AE1) in distal acidification is well established(2). There is evidence that -intercalated cells also have anapical H+-K+-ATPase (3) that may account for a significant fractionof HCO3- transport (4). Functionally, normal distal acidificationrequires an impermeant luminal membrane that is capable of sustaininglarge pH gradients, a lumen-negative potential difference inthe cortical collecting duct supporting both H+ and K+ secretionin this segment, and a rate of H+ secretion by the -intercalatedcells of the cortical and medullary collecting ducts (5). Therefore,distal renal tubular acidosis (dRTA) has been functionally classifiedinto gradient (backleak), voltage-dependent, and secretory-defecton the basis of the deranged physiologic mechanisms of urinaryacidification (6). In principle, the secretory-defect dRTA shouldbe caused by an impairment of distal H+ secretion, which mayarise from reduction in the number of intercalated cells, reductionin the quantity of H+-ATPase and/or H+-K+-ATPase in the intercalatedcells, or an abnormal distribution of proton pump(s) with areduced quantity at the apical membrane (5).
We and others have demonstrated the lack of H+-ATPase immunostainingin the intercalated cells in a few patients with secretory-defectdRTA (710). Mutations in H+-ATPase (11) and AE1 gene(1216) have recently been reported to cause dRTA. Here,we extend our investigation on the role of acid-base transporterdefect in the patients with secretory-defect dRTA by using immunohistochemicalmethods. This study suggests that reduction in the quantityof H+-ATPase and AE1 may be the major cause of functionallydiagnosed secretory-defect dRTA.
Patients
Diagnosis and classification of renal tubular acidosis weredone by the functional tests described below. Eleven patientswere enrolled in the group of secretory-defect dRTA. The causesof dRTA were idiopathic, tubulointerstitial nephropathies, andautoimmune disorders such as Sjogrens syndrome. Fourpatients with intrinsic renal diseases but without any defectin urinary acidification were enrolled in disease controls.Three patients who underwent surgical nephrectomy due to renalcell carcinoma served as normal controls. For immunohistochemistry,percutaneous renal biopsy specimens were obtained from the groupof secretory-defect dRTA and disease controls. Normal tissuefractions of the nephrectomized kidneys were also examined fromnormal controls.
Physiologic Tests for Urinary Acidification
To evaluate urinary acidification, we performed short-term ammoniumchloride loading, furosemide test, and sodium bicarbonate loading(17), as described below. The ammonium chloride loading testwas omitted in cases of overt acidemia (plasma HCO3- <18mmol/L). Urine pH was measured using a pH meter (Beckman, Fullerton,CA), and urine and blood pCO2 were measured by a blood gas analyzer(Nova, Waltham, MA). Serum and urine electrolytes and creatininewere measured on an autoanalyzer (Beckman, Fullerton, CA). Urineammonium was determined by the enzymatic method (18).
In the short-term ammonium chloride loading test, urine wascollected under mineral oil at 2-h intervals from 4 to 8 h afterthe administration of NH4Cl at a dose of 0.2 g/kg body wt. Bloodsamples were also taken at the end of each 2-h urine collectionto ensure that plasma the bicarbonate level decreased to 20mmol/L or less. For the furosemide test, urine was collectedat 2-h intervals from 4 to 6 h after an oral dose (1 mg/kg bodyweight) of furosemide. To increase the sensitivity of the testby ensuring a state of sodium avidity, 1 mg of fludrocortisonewas administered orally the evening before the testing. In thebicarbonate loading test, 2.75% NaHCO3 solution was infusedintravenously at a rate of 4 ml/kg per h. Urine and blood sampleswere taken at 2-h intervals until plasma bicarbonate concentrationreached 26 mmol/L. The values of urine-to-blood pCO2 gradientand fractional excretion of bicarbonate were calculated whenurine pH was raised to 7.5.
Immunohistochemistry from Renal Tissues
The renal tissues from the dRTA patients, disease controls andnormal controls were preserved in periodate-lysine-paraformaldehyde.The fixed tissues were dehydrated and embedded in polyesterwax, and sections were cut to 4-µm thickness and mountedon gelatin-coated glass slides. The sections were dewaxed withxylene and ethanol and were treated with methanolic H2O2 for30 min after rinsing under tap water. Before incubation withprimary antibodies, the sections were permeabilized by incubationfor 15 min in 0.5% Triton X-100 in phosphate-buffered saline(PBS), and then blocked with normal goat serum diluted 1:10in PBS for 15 min. Subsequently, the sections were incubatedovernight at 4°C with rabbit polyclonal antibodies to the70-kd catalytic subunit of the vacuolar H+-ATPase (kindly providedby Dr. Dennis Stone, University of Texas Southwestern, Dallas,TX) and erythrocyte Cl-/HCO3- exchanger, AE1 (kindly providedby Dr. Philip S. Low, Purdue University, West Lafayette, IL),a mouse monoclonal antibody (7C6) raised against chicken carbonicanhydrase II (kindly provided by Dr. Paul Linser, Whitney MarineLaboratory, University of Florida, Gainesville, FL), and a mousemonoclonal antibody to Na+-K+-ATPase 1 subunit (Upstate Biotechnology,Lake Placid, NY). The sections were rinsed in PBS and incubatedwith the biotinylated secondary antibody for 60 min and subsequentlywith the Vectastain ABC reagent for 60 min. After being rinsedwith 0.1 M Tris buffer, the sections were incubated with a mixtureof 0.05% 3.3'-diaminobenzidine and 0.033% H2O2 for 1 to 2 minat room temperature. After being rinsed with Tris buffer again,the sections were counterstained with hematoxylin and examinedwith light microscopy.
Table 1 shows the results of urinary acidification tests fromthe patients and controls. In normal controls, as expected,urine pH was low with NH4Cl loading and urine-to-blood pCO2gradient was large with NaHCO3 loading. In disease controls,who had glomerulopathy or tubulointerstitial nephritis but withoutevidences of acidification defect, urine pH was below 5.3 duringacidemia, which was induced by short-term NH4Cl loading, indicatingintact distal acidification.
Eleven patients with hyperchloremic metabolic acidosis werediagnosed to have secretory-defect dRTA on the basis of urinepH >5.5 during acidemia, normokalemia or hypokalemia, andurine-to-blood pCO2 <25 mmHg during bicarbonaturia. Eightpatients were hypokalemic, and the other three patients werenormokalemic. The serum anion gap, calculated by Na+ - (Cl-+ HCO3-), ranged from 4 to 10 mmol/L. The urine anion gap (Na++ K+ - Cl-) was positive in all of the patients, which is suggestiveof impaired urinary NH4+ excretion in the clinical setting ofhyperchloremic metabolic acidosis (19,20). Even with NH4Cl loading,urinary NH4+ excretion was not so high as in the controls (Table 1).As expected, urine pH was above 5.5 during acidemia thatwas spontaneous or induced by short-term NH4Cl loading. Additionally,urine pH did not decrease after an oral administration of furosemide,confirming a defect in H+ secretion (21). Urine pCO2 measuredafter intravenous NaHCO3 loading did not increase normally,and the urine-to-blood pCO2 gradient was <25 mmHg when itwas calculated under the condition of urine pH 7.5. Therefore,we concluded that our 11 patients had secretory-defect dRTA.However, in three patients, fractional excretion of bicarbonatewas >15% with intravenous NaHCO3 loading. These patientsseemed to have combined proximal and distal acidification defect.
Renal biopsy tissue was obtained from each patient, and immunohistochemistrywas carried out using antibodies to H+-ATPase, AE1, carbonicanhydrase II, and Na+-K+-ATPase 1 subunit. Renal biopsy specimensfrom the disease controls were also used for comparison. Wealso examined three different normal tissue sections from nephrectomizedkidneys for renal cell carcinoma (normal controls).
Figure 1 shows H+-ATPase immunohistochemistry in connectingtubule and cortical collecting duct from the normal controls,disease controls, and dRTA patients. In both normal controlsand disease controls, the immunostaining of H+-ATPase was stronglypositive on the apical membranes of -intercalated cells. However,the secretory-defect dRTA patients revealed absolute decreasein immunostaining of H+-ATPase along the connecting tubule andcollecting duct.
Figure 1. Differential interference contrast (DIC) micrographs of renal cortex from normal controls (A and B), disease controls (C and D), and secretory-defect distal renal tubular acidosis (dRTA) patients (E and F) illustrating immunostaining for H+-ATPase. In normal controls, numerous intercalated cells with apical (arrows) and diffuse (open arrow) H+-ATPase immunoreactivity are observed in the connecting tubule (CNT) and cortical collecting duct (CCD). In disease controls, intercalated cells with strong H+-ATPase immunoreactivity (arrows) are seen in the CNT and CCD. In secretory-defect dRTA patients, H+-ATPaselabeled intercalated cells are decreased both in number and in intensity of immunoreactivity for H+-ATPase along the CNT and CCD. PT, proximal tubule. Magnification, x400.
The H+-ATPase immunostaining was moderately positive in proximaltubule cells of disease controls and normal controls. Althoughmost dRTA patients showed positive H+-ATPase immunostainingin proximal tubule, three dRTA patients had negative or traceH+-ATPase immunoreactivity in their proximal tubule cells (Figure 2).We could not find any significant correlation between thelack of proximal tubule H+-ATPase immunoreactivity and the presenceof combined proximal acidification defect.
Figure 2. DIC micrographs illustrating immunostaining for H+-ATPase in the PT from normal control (A), disease control (B), and a secretory-defect dRTA patient (C). Strong positive immunoreactivity of H+-ATPase in normal and disease controls is observed in the PT. In the secretory-defect dRTA patient, who has combined defect in proximal acidification, H+-ATPase immunoreactivity is decreased in the PT compared with controls. Magnification, x400.
Figure 3 shows AE1 immunohistochemistry in collecting duct fromthe normal controls, disease controls, and dRTA patients. Inboth normal controls and disease controls, the immunostainingof AE1 was strongly positive on the basolateral membranes of-intercalated cells. However, most of the secretory-defect dRTApatients revealed absolute decrease in immunostaining of AE1along the connecting tubule and collecting duct.
Figure 3. DIC micrographs of renal cortex from normal control (A), disease control (B), and secretory-defect dRTA patients (C and D) illustrating immunostaining for anion exchanger-1 (AE1). In normal and disease controls, a lot of intercalated cells (arrows) with basolateral immunostaining for AE1 are seen in the CNT and CCD. In secretory-defect dRTA patients, only a few intercalated cells weakly labeled with AE1 are seen in the connecting tubule and collecting ducts. Magnification, x400.
Carbonic anhydrase II (CA II) is present in the intercalatedcells to facilitate acid-base transport in the distal nephron.The CA II immunoreactivity was also markedly different betweencontrols and secretory-defect dRTA patients (Figure 4). In bothnormal controls and disease controls, the immunostaining forCA II was strong in the intercalated cells of the connectingtubule and collecting duct. In the secretory-defect dRTA patients,however, immunostaining for CA II in the connecting tubule andcollecting duct was markedly decreased in intensity.
Figure 4. DIC micrographs of renal cortex from normal control (A and B), disease control (C and D), and a secretory-defect dRTA patient (E and F) illustrating immunostaining for carbonic anhydrase II (CA II) in the CNT (A, C, and E) and CCD (B, D, and F). In normal and disease control, intercalated cells (arrows) in both the CNT and CCD exhibit strong immunoreactivity. In the secretory-defect dRTA patient, however, immunostaining for CA II both in CNT and CCD is markedly decreased in intensity. Magnification, x400.
We also tested Na+-K+-ATPase immunoreactivity in the kidneyto verify whether the absence of H+-ATPase and AE1 immunostainingwere specific findings or not. In intercalated cells, the Na+-K+-ATPase1 subunit immunoreactivity in our wax sections was too weakto compare between the patients and controls. However, the Na+-K+-ATPase1 subunit immunostaining was equally strong on the basolateralmembranes of distal convoluted tubules and thick ascending limbsin the normal controls, disease controls and secretory-defectdRTA patients as well (Figure 5). Therefore, the lack of H+-ATPaseand AE1 immunostaining was thought to be selective in secretory-defectdRTA.
Fig. 5. DIC micrographs of renal cortex from normal control (A), disease control (B), and a secretory-defect dRTA patient (C) illustrating immunostaining for Na-K-ATPase 1 subunit. Positive immunoreactivity of Na-K-ATPase in normal and disease controls is observed in the distal convoluted tubules and thick ascending limbs (*). The secretory-defect dRTA patient also shows strong immunostaining for Na-K-ATPase in both nephron segments. Magnification, x400.
Table 2 summarizes relative immunoreactivities of H+-ATPase,AE1, and Na+-K+-ATPase from the kidneys of normal controls,disease controls, and secretory-defect dRTA patients. The H+-ATPaseimmunoreactivity in -intercalated cells was almost absent inall of the 11 patients with secretory-defect dRTA. Notably,more than half (7 of 11) of them were accompanied by negativeAE1 immunoreactivity in -intercalated cells.
We present here important structural-functional correlates throughour immunohistochemical study of renal tissue using antibodiesagainst H+-ATPase and AE1 in renal biopsy specimens from secretory-defectdRTA patients in whom careful physiologic studies were performed.It was concluded that functionally diagnosed secretory-defectdRTA may be caused by H+-ATPase (with or without AE1) defectin intercalated cells. Although there have been some case reportsdemonstrating the lack of H+-ATPase and/or AE1 in the collectingducts of the patients with dRTA, we confirmed the absolute reductionof these acid-base transporters in our collection of secretory-defectdRTA patients. In addition, we demonstrated coexistence of H+-ATPaseand AE1 defect in most of our secretory-defect dRTA patients.
The existence of secretory-defect dRTA has been reasonably wellcharacterized in patients with different diseases causing acquireddRTA (22). Derangements of collecting duct function determinedgenetically (e.g., hereditary dRTA), associated with structuralabnormalities (e.g., medullary sponge kidney), or immunologicallymediated (e.g., Sjogrens syndrome) could all interferewith the integrity of the proton pump secretory apparatus (22).Our dRTA patients were functionally diagnosed on the basis ofthe following results to have a secretory defect. First, urinepH was not lowered below 5.5, not only during acidemia, butalso after stimulation of sodium-dependent distal acidificationby the administration of furosemide. Second, the urine pCO2measured after bicarbonate loading did not increase normally,reflecting that the rate of collecting duct H+ secretion isreduced.
In the collecting duct, H+-ATPase is likely responsible formuch of the H+ secretion that takes place in this segment (23).Therefore, the secretory-defect dRTA could be due to any alterationscausing an impairment of the collecting duct acidification byprimarily interfering with the H+-ATPase. Cohen et al. (7) firstdemonstrated absence of H+-ATPase staining in collecting ductcells from a renal biopsy specimen from a patient with secretory-defectdRTA and Sjogrens syndrome. They found the presence onelectron microscopy of cells with typical ultrastructural featuresof intercalated cells, and they suggested that the distal acidificationdefect was due to the absence of intact H+-ATPase rather thanthe selective loss of -intercalated cells. We have also reportedthat a patient with idiopathic hypokalemic dRTA (Albrightsdisease) had absence of H+-ATPase staining in the intercalatedcells (10). Taken together with the results from our currentstudy, it is strongly indicated that lack of H+-ATPase in theintercalated cells of the collecting duct may be the chief cellularmechanism responsible for the secretory-defect dRTA.
We found that not only H+-ATPase but also AE1 immunostainingwere absent in the -intercalated cells in the majority of oursecretory-defect dRTA patients, suggesting failure of -intercalatedcells to express both the H+-ATPase and AE1 proteins. Althoughthe reason is unclear, few -intercalated cells were noted inour biopsy tissue. Therefore, we could not describe any changesin the -intercalated cells. In addition, the immunoreactivityfor both H+-ATPase and AE1 was so weak in the secretory-defectdRTA patients that we could not analyze further on subtype defectsin the intercalated cells.
Bastani and associates (8,9) previously examined kidney biopsiesfrom two patients with Sjogrens syndrome, and neitherpatient showed any immunostaining of intercalated cells withthe antibodies against H+-ATPase and AE1. The ultrastructuralpresence of intercalated cells and the absence of discerniblestaining for H+-ATPase and AE1 suggest that the defect in protonsecretion may represent a defect involving the assembly of atleast two of the ion transport pumps that are essential forthe normal maintenance of acid-base homeostasis by the intercalatedcells (8). Consistent with this view, we found that CA II immunostainingin the intercalated cells of the connecting tubule and corticalcollecting duct was markedly decreased in the secretory-defectdRTA patients. The parallel decrease in H+-ATPase and CA IIexpression might be explained by the fact that the H+-secretingprocess is accelerated by cytosolic or membrane-associated carbonicanhydrase in most H+-secreting cells (24).
Deficiency of CA II is an autosomal recessive disorder producinga distinctive syndrome of renal tubular acidosis, osteopetrosis,cerebral calcification, and mental retardation (25), and mostpatients with CA II deficiency syndrome have both proximal anddistal components to the renal tubular acidosis (26). Threepatients from our current study were diagnosed on the basisof high fractional excretion of bicarbonate to have combinedproximal and distal acidification defect. However, we couldnot find any clinical evidence for CA II deficiency syndromein these patients. Our immunostaining for CA II in the proximaltubule was weakly positive in both the patients and controls.Although we found negative or trace H+-ATPase immunostainingin proximal tubule cells in three dRTA patients, there was noclear association between the lack of proximal tubule H+-ATPaseimmunoreactivity and the presence of combined proximal acidificationdefect.
The Na+-K+-ATPase, located in the basolateral membranes of renaltubular epithelial cells, also has a role in pathophysiologyof urinary acidification defects (27), because H+-ATPase activitycan be secondarily affected if Na+-K+-ATPase is altered (28).In this study, intercalated cells did not show enough Na+-K+-ATPaseimmunostaining to compare the patients with the controls. Thedistal tubules, on the other hand, showed strong Na+-K+-ATPaseimmunoreactivity in both the patients and the controls. Thesefindings seemed compatible with the results of Na+-K+-ATPaseactivity measured in individual segments of the nephron (29).We believe that intrinsic failure of H+-ATPase would be associatedwith features of dRTA.
The pathogenic mechanisms causing the absence of immunostainingfor H+-ATPase and/or AE1 remain elusive. Although the natureof the defects is unknown, point mutations producing abnormalacid-base transporters may underlie primary dRTA in adults.A variety of tubulointerstitial disease may produce secondarydRTA. Conceivably, the inflammatory process prevents the normalassembly and/or insertion of H+-ATPase into the apical plasmamembrane. However, the renal tissue from our dRTA patients revealedonly occasional findings of interstitial infiltration, and thusit appears that other mechanisms may play a role in the developmentof the acidification defect. We postulate existence of as-yet-unknownrenal molecules that may affect synthesis, trafficking, or degradationof acid-base transporter protein.
Finally, most of our dRTA patients were hypokalemic. Hypokalemiais presumably due to increased distal potassium secretion, possiblymediated by secondary hyperaldosteronism and increased distaldelivery of sodium or a defect in H+-K+-ATPase (6,30). Unfortunately,the lack of antibodies prevented us from testing the possiblerole of a deficiency of H+-K+-ATPase as the mechanism underlyinghypokalemic dRTA. Further studies are needed to elucidate arole for H+-K+-ATPase in the pathogenesis of hypokalemic dRTA.
Acknowledgments
This work is supported by the Grant 97-N102-04-A-05 fromMinistry of Science and Technology of Korea and by the BrainKorea 21 Project from Korea Research Foundation. The authorsare indebted to Young-Hee Kim and So-Young Kim for technicalassistance.
Sabatini S, Kurtzman NA: Overall acid-base regulation by the kidney.In Seldin DW, Giebisch G, (eds.): Regulation of Acid-Base Balance. New York, Raven Press, 1989,pp 185210
Gluck SL, Iyori M, Holliday LS, Kostrominova T, Lee BS: Distal urinary acidification from Homer Smith to the present. Kidney Int 49: 16601664, 1996[Medline]
Bastani B: Colocalization of H-ATPase and H, K-ATPase immunoreactivity in the rat kidney. J Am Soc Nephrol 5: 14761482, 1995[Abstract]
Gifford JD; Rome L; Galla JH: H+-K+-ATPase activity in rat collecting duct segments. Am J Physiol 262: 692F695, 1992
Bastani B, Gluck SL: New insights into the pathogenesis of distal renal tubular acidosis. Miner Electrolyte Metab 22: 396409, 1996[Medline]
Kurtzman NA: Disorders of distal acidification. Kidney Int 38: 720727, 1990[Medline]
Cohen EP, Bastani B, Cohen MR, Kolner S, Hemken P, Gluck SL: Absence of H+-ATPase in cortical collecting tubules of a patient with Sjogrens syndrome and distal renal tubular acidosis. J Am Soc Nephrol 3: 264271, 1992[Abstract]
DeFranco PE, Haragsim L, Schmitz PG, Bastani B: Absence of vacuolar H+-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjogrens syndrome. J Am Soc Nephrol 6: 295301, 1995[Abstract]
Bastani B, Haragsim L, Gluck S, Siamopoulos KC: Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sjogrens syndrome (letter). Nephrol Dial Transplant 10: 908909, 1995[Free Full Text]
Joo KW, Jeon US, Han JS, Ahn C, Kim S, Lee JS, Kim GH, Cho YS, Kim YH, Kim J: Absence of H+-ATPase in the intercalated cells of renal tissues in classic distal renal tubular acidosis. Clin Nephrol 49: 226231, 1998[Medline]
Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha V, Lifton RP: Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21: 8490, 1999[CrossRef][Medline]
Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, Unwin RJ, Wrong O, Tanner MJ: Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 100: 16931707, 1997[Medline]
Jarolim P, Shayakul C, Prabakaran D, Jiang L, Stuart-Tilley A, Rubin HL, Simova S, Zavadil J, Herrin JT, Brouillette J, Somers MJ, Seemanova E, Brugnara C, Guay-Woodford LM, Alper SL : Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem 273: 63806388, 1998[Abstract/Free Full Text]
Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, di Pietro A, Walker WG, Lifton RP: Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 95: 63376342, 1998[Abstract/Free Full Text]
Tanphaichitr VS, Sumboonnanonda A, Ideguchi H, Shayakul C, Brugnara C, Takao M, Veerakul G, Alper SL: Novel AE1 mutations in recessive distal renal tubular acidosis. Loss-of-function is rescued by glycophorin A. J Clin Invest 102 21732179, 1998[Medline]
Lash JP, Arruda JAL: Laboratory evaluation of renal tubular acidosis. Clin Lab Med 13: 117129, 1993[Medline]
Mondaz A, Ehrlich GE, Seegmiller JE: An enzymatic determination of ammonia in biological fluids. J Lab Clin Med 66: 526531, 1965[Medline]
Batlle DC, Hizon M, Cohen E, Gutterman C, Gupta R: The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 318: 594599, 1988[Abstract]
Kim GH, Han JS, Kim YS, Joo KW, Kim S, Lee JS: Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis. Am J Kidney Dis 27: 4247, 1996[Medline]
Batlle DC: Segmental characterization of defects in collecting tubule acidification. Kidney Int 30: 54654, 1986[Medline]
Batlle D, Flores G: Underlying defects in distal renal tubular acidosis: new understandings. Am J Kidney Dis 27: 896915, 1996[Medline]
Kleinman JG: Proton ATPases and urinary acidification. J Am Soc Nephrol 5: S611, 1994[Abstract]
Hamm LL, Alpern RJ: Cellular mechanisms of renal tubular acidification.In: The Kidney. Physiology & Pathophysiology, 3rd ed., edited by Seldin DW, and Giebisch G, Philadelphia, Lippincott Williams & Wilkins, 2000,pp 19351979
Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci USA 89: 18041808, 1992[Abstract/Free Full Text]
Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, Vainsel M, Baluarte HJ, Gruskin A, Al-Mosawi M: Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med 313: 139145, 1985[Abstract]
Mujais SK: Transport enzymes and renal tubular acidosis. Semin Nephrol 18: 7482, 1998[Medline]
Sabatini S: Experimental studies in distal urinary acidification: bringing the bedside to the bench. Semin Nephrol 19: 188194, 1999[Medline]
Garg LC, Knepper MA, Burg MB: Mineralocorticoid effects on Na-K-ATPase in individual nephron segments. Am J Physiol 240: F536544, 1981[Abstract/Free Full Text]
Smulders YM, Frissen PHJ, Slaats EH, Silberbusch J: Renal tubular acidosis. Pathophysiology and diagnosis. Arch Intern Med 156: 16291636, 1996
Received for publication January 17, 2002.
Accepted for publication February 2, 2002.
This article has been cited by other articles:
S. Walsh, C. M. Turner, A. Toye, C. Wagner, P. Jaeger, C. Laing, and R. Unwin Immunohistochemical comparison of a case of inherited distal renal tubular acidosis (with a unique AE1 mutation) with an acquired case secondary to autoimmune disease
Nephrol. Dial. Transplant.,
March 1, 2007;
22(3):
807 - 812.
[Full Text][PDF]
C. A. Wagner, K. E. Finberg, S. Breton, V. Marshansky, D. Brown, and J. P. Geibel Renal Vacuolar H+-ATPase
Physiol Rev,
October 1, 2004;
84(4):
1263 - 1314.
[Abstract][Full Text][PDF]